Expansion of regulatory T cells via IL-2/anti-IL-2 mAb complexes suppresses experimental myasthenia.

Liu R, Zhou Q, La Cava A, Campagnolo DI, Van Kaer L, Shi FD
Eur J Immunol. 2010 40 (6): 1577-89

PMID: 20352624 · PMCID: PMC3600978 · DOI:10.1002/eji.200939792

Human autoimmune diseases are often characterized by a relative deficiency in CD4(+)CD25(+) regulatory T cells (Treg). We therefore hypothesized that expansion of Treg can ameliorate autoimmune pathology. We tested this hypothesis in an experimental model for autoimmune myasthenia gravis (MG), a B-cell-mediated disease characterized by auto-Ab directed against the acetylcholine receptor within neuromuscular junctions. We showed that injection of immune complexes composed of the cytokine IL-2 and anti-IL-2 mAb (JES6-1A12) induced an effective and sustained expansion of Treg, via peripheral proliferation of CD4(+)CD25(+)Foxp3(+) cells and peripheral conversion of CD4(+)CD25(-)Foxp3(-) cells. The expanded Treg potently suppressed autoreactive T- and B-cell responses to acetylcholine receptor and attenuated the muscular weakness that is characteristic of MG. Thus, IL-2/anti-IL-2 mAb complexes can expand functional Treg in vivo, providing a potential clinical application of this modality for treatment of MG and other autoimmune disorders.

MeSH Terms (14)

Animals Antibodies, Monoclonal Antigen-Antibody Complex B-Lymphocytes Cell Separation Cytokines Enzyme-Linked Immunosorbent Assay Female Flow Cytometry Interleukin-2 Lymphocyte Activation Mice Myasthenia Gravis, Autoimmune, Experimental T-Lymphocytes, Regulatory

Connections (1)

This publication is referenced by other Labnodes entities: